Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
19 avr. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
James Brady Joins Verona Pharma as Non-Executive Director
14 mars 2022 03h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
03 mars 2022 02h00 HE
|
Verona Pharma plc
Phase 3 ENHANCE program on track to report top-line COPD data in 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., March 03, 2022 (GLOBE NEWSWIRE) -- Verona...
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
17 févr. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
24 janv. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
05 janv. 2022 02h00 HE
|
Verona Pharma plc
ENHANCE-2 Screening Complete with Full Enrollment Expected in January 2022 ENHANCE Phase 3 Program on Track to Report Top-line Data in 2022 LONDON and RALEIGH, N.C., Jan. 05, 2022 (GLOBE...
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
04 janv. 2022 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
16 déc. 2021 02h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today...
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
09 nov. 2021 02h00 HE
|
Verona Pharma plc
Enrollment in ENHANCE-1 48-week subset and ENHANCE-2 expected to complete around year-end 2021ENHANCE Phase 3 program on track to report top-line data in 2022Conference call today at 9:00 a.m....
Verona Pharma Announces November 2021 Investor Conference Participation
01 nov. 2021 03h00 HE
|
Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...